Mechanistic Insights Into Realgar-Induced CNS Toxicity: The Role of OTC Inhibition and Ornithine Regulation

Study Background and Research Question

Realgar, a mineral-based traditional Chinese medicine (TCM) containing arsenic, has been deployed for millennia in various clinical contexts. While the therapeutic applications of realgar are well-documented, its safety profile remains controversial, especially with respect to central nervous system (CNS) toxicity emerging from chronic or excessive use. The brain’s susceptibility to arsenic is a longstanding concern, yet the precise molecular pathways linking hepatic metabolism to CNS dysfunction remain poorly characterized. The reference study (Ye et al., 2025) addresses a critical gap: how realgar-induced hepatic dysfunction intersects with astrocyte metabolism and neurotoxicity through the liver–brain axis, focusing particularly on the regulation of the urea cycle intermediate L-Ornithine and its downstream effects.

Key Innovation from the Reference Study

The study introduces a novel mechanistic pathway in which realgar-derived arsenic disrupts hepatic ornithine transcarbamylase (OTC) activity, causing systemic and CNS-specific accumulation of L-Ornithine (also known as (S)-2,5-diaminopentanoic acid). This excess ornithine interacts directly with the transcription factor ZBTB7A in astrocytes, resulting in repression of genes encoding key glycolytic enzymes. The research bridges metabolic enzyme assay findings with transcriptomic and behavioral evidence, revealing that disruption of the ammonia detoxification pathway in the liver has far-reaching consequences for astrocyte bioenergetics and neuronal support functions. This cross-organ axis is supported by direct molecular docking data and functional rescue experiments with chrysophanol, a protective agent.

Methods and Experimental Design Insights

The investigation by Ye et al. utilizes an integrated approach, combining:

• Animal models featuring conditional genetic interventions (Zbtb7a knockdown in astrocytes and hepatic OTC overexpression), with chronic realgar exposure to induce arsenic toxicity.
• In vitro studies with C8-D1A astrocyte cell lines, transfected with si-Zbtb7a and exposed to both inorganic arsenic (iAs³⁺) and exogenous L-Ornithine, to dissect cell-intrinsic responses.
• Single-cell RNA sequencing and metabolomic profiling to capture cell-type specific transcriptional and metabolic perturbations.
• Neurobehavioral assays (learning, memory, exploration, and anxiety-like behavior) in mice to correlate molecular changes with functional deficits.
• Molecular biological and histopathological assessments of brain and liver tissue.

This multipronged design provides strong evidence for causality between hepatic OTC inhibition, ornithine accumulation, and CNS dysfunction.

Core Findings and Why They Matter

Key results from the reference study (Ye et al., 2025) include:

• Arsenic derived from realgar crosses the blood–brain barrier and accumulates in the frontal lobe, targeting astrocytes as primary responders.
• Within astrocytes, arsenic triggers ZBTB7A-mediated transcriptional repression of glycolytic genes (Aldoa, Ldha, Pgam1), reducing lactate production and leading to an energy deficit in the frontal cortex.
• This energy deficit manifests as increased astrocyte apoptosis, oxidative damage, and behavioral impairments (memory loss, reduced exploration, anxiety-like symptoms).
• Realgar also inhibits hepatic OTC, disrupting the urea cycle and causing systemic and CNS ornithine accumulation. This is verified by elevated ornithine levels in both blood and frontal lobe tissue.
• Molecular docking analysis demonstrates direct binding of ornithine to ZBTB7A, suggesting a regulatory mechanism whereby excess ornithine exacerbates the repression of glycolytic gene expression in astrocytes.
• Chrysophanol administration antagonizes these toxic effects by rescuing both hepatic and CNS metabolic functions.

The study’s findings underscore the importance of urea cycle intermediates in CNS function and highlight the vulnerability of astrocyte glycolysis to disturbances in hepatic amino acid metabolism. This supports a growing body of evidence linking peripheral metabolic disorders to neurological outcomes, with L-Ornithine emerging as a functional bridge between liver pathology and brain energy homeostasis. The work also provides new molecular targets (OTC, ZBTB7A) for future interventions in TCM-induced neurotoxicity and possibly metabolic encephalopathies.

Protocol Parameters

• Realgar exposure: Chronic dosing in rodents to model cumulative arsenic toxicity; control for duration and dose to avoid acute systemic effects.
• Conditional OTC overexpression: Liver-targeted gene delivery (e.g., via AAV vectors) prior to realgar treatment; verify OTC activity by urea cycle metabolite quantification.
• Astrocyte Zbtb7a knockdown: GFAP promoter-driven shRNA or CRISPR strategies in vivo; siRNA transfection in C8-D1A cell lines for in vitro assays.
• L-Ornithine supplementation: Dose and timing based on metabolomic readouts; monitor for cellular toxicity and ZBTB7A activation in astrocytes.
• Chrysophanol intervention: Administer during or after realgar challenge to assess rescue of astrocyte glycolytic function and hepatic OTC activity.
• Metabolic enzyme assays: Quantify OTC and glycolytic enzyme activities using established biochemical protocols; validate with transcript and protein expression analysis.

Comparison with Existing Internal Articles

The mechanistic axis identified by Ye et al. aligns with and extends several recent syntheses of L-Ornithine’s research utility. For instance, "L-Ornithine in Ammonia Detoxification & CNS Toxicity Models" discusses experimental workflows for bridging hepatic urea cycle dynamics with CNS function, echoing the reference study’s focus on the liver–brain axis. The article "L-Ornithine: Urea Cycle Intermediate for Metabolic Research" provides background on L-Ornithine as a non-proteinogenic amino acid essential for nitrogen disposal, further contextualizing its role as a metabolic mediator. Notably, the internal review "OTC-Mediated Ornithine and Astrocyte Glycolysis in Realgar CNS Toxicity" directly summarizes the connection between hepatic OTC suppression and central astrocyte dysfunction, supporting the interpretation that metabolic crosstalk is a critical determinant in neurotoxicity.

Limitations and Transferability

Despite the comprehensive approach, several caveats should be considered. The primary models employ rodent genetics and immortalized astrocyte lines, which may not fully recapitulate human hepatic or neural complexity. Chronic realgar dosing and the use of single-cell transcriptomic platforms provide high-resolution insight, but interspecies differences in OTC regulation and blood–brain barrier permeability could affect translational relevance. Moreover, while the link between ornithine and ZBTB7A is substantiated by docking and expression data, the exact structural basis and downstream signaling remain partially unresolved. These limitations highlight the need for further studies in humanized models and patient-derived cells.

Research Support Resources

Researchers investigating the intersection of amino acid metabolism and CNS function can leverage high-purity L-Ornithine (SKU B8919, (S)-2,5-diaminopentanoic acid) to replicate or extend these workflows. L-Ornithine is validated for use in aqueous and alcoholic solutions, supporting both metabolic and neurotoxicity assays. For deeper protocol insights, refer to recent guides such as "L-Ornithine in Ammonia Detoxification & CNS Toxicity Models", which offers troubleshooting advice and experimental design strategies for the study of urea cycle intermediates and liver–brain axis modulation.